- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
ANDA Litigation Settlements
Spring 2013
![GENERICally Speaking: A Hatch Waxman Litigation Bulletin](/-/media/images/newsletters/generically-speaking-social-graphics/generically-speaking-nwsltr-badge.jpg?la=en&h=160&w=390&la=en&hash=314B8432ED62E0647D7FC4565EC18B79)
Case Name | Drug | Patent No(s). | Publicly Available Terms |
In re: Nebivolol patent litigation, 12-5026 (N.D. Ill.) | Bystolic® (nebivolol tablets) | 6,545,040 |
Forest Labs., Inc. to give Glenmark Pharma. Ltd. a license to release generic nebivolol either when the FDA approves Glenmark’s ANDA or three months prior to patent expiration, whichever is first. |
Mallinckrodt LLC v. Apotex, Inc., 12-1087 (D.Del.) | Pennsaid® (diclofenac sodium topical solution) | 8,217,078 | Apotex may release its generic product, a 1.5% by weight solution, 45 days after Mallinckrodt makes its first commercial shipment of Pennsaid 2%, a new version of the drug, or April 1, 2014, whichever comes first. Apotex may also release its 1.5% version earlier under certain unspecified circumstances. |
Purdue Pharma LP v. Ranbaxy Inc, 10-3734 (S.D.N.Y.) | OcyContin® (oxycodone hydrochloride extended-release tablets) | 7,674,799; 7,674,800; 7,683,072 |
Ranbaxy admits to infringing the asserted patents. Ranbaxy waived possible antitrust or other claims against Purdue.
|
AstraZeneca Pharma. LP v. Torrent Pharma. Ltd., 10-4205 (D.N.J.) | Seroquel XR® (quetiapine fumarate extended-release tablets) | 5,948,437 |
Torrent admits that AstraZeneca’s patent is enforceable and valid. Torrent agrees not to produce its generic version of the drug until November 2016. |
Gilead Sciences Inc. v. Teva Pharma. USA Inc., 10-1796 (S.D.N.Y.) | Viread® (tenofovir disoproxil fumarate tablets) | 5,922,695; 5,935,946; 5,977,089; 6,043,230 | Teva will be allowed to launch its generic product in December 2017. |
Shionogi Pharma. Inc. v. Mylan Inc., 10-0135 (D. Del.) | Fortamet® (metformin hydrochloride extended-release tablets) | 6,099,859; 6,866,866 |
Mylan may launch a generic version of Fortamet on Aug. 1 or earlier under certain conditions. |
AstraZeneca UK Ltd. v. Watson Pharma. Inc., 10-0915 (D. Del.) | Crestor® (rosuvastatin calcium) | RE37,314 | Actavis is allowed to launch its generic product on May 2, 2016—67 days before the expiration of AstraZeneca’s pediatric exclusivity period. Actavis has conceded the validity and enforceability of the ’314 patent, and has agreed not to further appeal a December decision by the Federal Circuit upholding the validity of the patent. Actavis will pay a fee equal to 39% of the net sales of its rosuvastatin drugs to AstraZeneca for that 67-day early launch period. |
Allergan Inc. v. Athena Cosmetics Inc., 07-1316 (C.D. Ca.) | Latisse® (bimatoprost ophthalmic solution) | 6,262,105; 7,351,404; 7,388,029 | N/A |
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.